Back to top
more

TURNING PT THER (TPTX)

(Delayed Data from NSDQ)

$32.54 USD

32.54
134,430

-1.16 (-3.44%)

Updated May 3, 2019 04:00 PM ET

After-Market: $32.56 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is IQ Chaikin U.S. Small Cap ETF (CSML) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for CSML

Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for CSML

Bristol-Myers (BMY) Q2 Earnings, Sales Beat on Eliquis, Opdivo

by Zacks Equity Research

Bristol-Myers (BMY) earnings and sales beat estimates in the second quarter of 2022 on the back of Eliquis and Opdivo and a lesser decline in sales of Revlimid.

Bristol-Myers (BMY) to Post Q2 Earnings: What is in the Cards?

by Zacks Equity Research

Investors will likely focus on the demand for Eliquis and Opdivo along with incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q2 results. Operating expenses might have jumped.

Bristol Myers (BMY) Up 20.4% YTD: Will the Momentum Continue?

by Zacks Equity Research

Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.

The Zacks Analyst Blog Highlights Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics

by Zacks Equity Research

Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics are part of Zacks top Analyst Blog.

Biotech Stock Roundup: BMY's Acquisition, REGN to Buy Libtayo & More

by Zacks Equity Research

Acquisition and other updates from Bristol Myers (BMY) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

Bristol Myers (BMY) to Acquire Turning Point, Withdraws sBLA

by Zacks Equity Research

Bristol Myers (BMY) is set to acquire Turning Point to bolster its oncology portfolio. The company also withdraws its sbLA for Reblozyl.

What Makes Turning Point Therapeutics (TPTX) a New Buy Stock

by Zacks Equity Research

Turning Point Therapeutics (TPTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics

by Zacks Equity Research

Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics

Kinjel Shah headshot

5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty

by Kinjel Shah

Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry in 2021. However, with demand trends expected to improve, USNA, RDUS, ONCT, ORGO and TPTX may prove to be good additions to one's portfolio.

Turning Point Therapeutics (TPTX) Looks Good: Stock Adds 5.3% in Session

by Zacks Equity Research

Turning Point Therapeutics (TPTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Turning Point Therapeutics (TPTX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Turning Point Therapeutics (TPTX) delivered earnings and revenue surprises of 14.58% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Biotech Stock Q1 Earnings Due on May 12: ADPT, VIR, TPTX

by Kinjel Shah

Let us take a look at three biotech companies due to release their first-quarter financial results on May 12.

    Will Turning Point Therapeutics Continue to Surge Higher?

    by Zacks Equity Research

    As of late, it has definitely been a great time to be an investor Turning Point Therapeutics

    Is Turning Point Therapeutics (TPTX) Stock a Solid Choice Right Now?

    by Zacks Equity Research

    Turning Point Therapeutics (TPTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

    The Zacks Analyst Blog Highlights: BYND, ZM, KRTX, TPTX and SILK

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: BYND, ZM, KRTX, TPTX and SILK

    Manaswita Ghosh Dutta headshot

    5 Best Performing IPOs of 2019

    by Manaswita Ghosh Dutta

    This year's IPOs performed impressively on the back of strong innovation and a solid balance sheet.

    Turning Point (TPTX) Catches Eye: Stock Jumps 6.1%

    by Zacks Equity Research

    Turning Point (TPTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

    The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme

    Nitish Marwah headshot

    4 Best-Performing IPOs So Far in 2019

    by Nitish Marwah

    Companies that went public this year and did well in terms of price performance did so on the back of solid financials, positive cash flows and growing revenues.